Study Evaluating AMG 424 in Subjects With Multiple Myeloma

Summary

A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.

Timeline

Start

2018-07-31

Primary completion

2020-06-19

Completion

2020-06-19

Outcome

Outcome not reported

Stopped (Business): “Previous sponsor business decision not to proceed with the AMG 424 asset.”

Drugs

Indications